Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Incyte Corporation

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Retifanlimab,Carboplatin,Paclitaxel

            Therapeutic Area: Oncology Product Name: INCMGA00012

            Highest Development Status: Phase III Product Type: Large molecule

            Recipient: MacroGenics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 30, 2020

            Details:

            MacroGenics and Incyte have each established multiple development programs for retifanlimab, evaluating the anti-PD-1 molecule either as monotherapy or in combination with other agents.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Baricitinib,Remdesivir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Olumiant

            Highest Development Status: Phase III Product Type: Small molecule

            Recipient: Eli Lilly

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 19, 2020

            Details:

            The EUA is based on data from the ACTT-2, a randomized double-blind, placebo-controlled study to evaluate the efficacy and safety of baricitinib in combination with remdesivir vs placebo with remdesivir in hospitalized patients with or without oxygen requirements.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MCLA-145

            Therapeutic Area: Oncology Product Name: MCLA-145

            Highest Development Status: Phase I Product Type: Large molecule

            Recipient: MERUS LABS INTERNATIONAL INC

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 09, 2020

            Details:

            MCLA-145 is currently being evaluated in a Phase 1 open-label, multicenter dose escalation study, including a safety dose expansion phase, in patients with solid tumors.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Baricitinib

            Therapeutic Area: Dermatology Product Name: Olumiant

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: Eli Lilly

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 31, 2020

            Details:

            New data for baricitinib for the treatment of moderate to severe atopic dermatitis showed that baricitinib 4-mg and 2-mg dose groups were able to maintain clear or almost clear skin response rates through the 68-week treatment period.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Baricitinib

            Therapeutic Area: Dermatology Product Name: Olumiant

            Highest Development Status: Phase III Product Type: Small molecule

            Recipient: Eli Lilly

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 30, 2020

            Details:

            Data support baricitinib's ongoing Phase 3 program and potential to be the first approved medicine for people living with alopecia areata (AA).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ruxolitinib

            Therapeutic Area: Dermatology Product Name: Jakafi

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 29, 2020

            Details:

            Results reinforce that ruxolitinib cream treatment results in a rapid, substantial and sustained reduction in itch. Results also demonstrate improvement in patient-reported perceptions of sleep quality, sleep depth and restoration associated with sleep.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pemigatinib

            Therapeutic Area: Oncology Product Name: Pemazyre

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 26, 2020

            Details:

            The New Drug Submission is based on data from the FIGHT-202 study evaluating pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Baricitinib,Remdesivir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Olumiant

            Highest Development Status: Phase III Product Type: Small molecule

            Recipient: Eli Lilly

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 08, 2020

            Details:

            Baricitinib in combination with remdesivir reduced time to recovery and improved clinical outcomes for patients with COVID-19 infection compared with remdesivir. 35% decrease in death rate through Day 29 was observed in patients treated with baricitinib plus remdesivir.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Retifanlimab,Pemetrexed,Cisplatin

            Therapeutic Area: Oncology Product Name: INCMGA00012

            Highest Development Status: Phase III Product Type: Large molecule

            Recipient: MacroGenics

            Deal Size: $735.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration September 21, 2020

            Details:

            The milestone was triggered by the initiation of the Phase 3 POD1UM-304 clinical trial, evaluating the efficacy and safety of retifanlimab with platinum-based chemotherapy in patients with metastatic squamous and non-squamous non-small cell lung cancer (NSCLC).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Baricitinib

            Therapeutic Area: Dermatology Product Name: Olumiant

            Highest Development Status: Phase III Product Type: Small molecule

            Recipient: Eli Lilly

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 18, 2020

            Details:

            If approved, baricitinib would become the first JAK inhibitor indicated to help treat patients with AD. The positive opinion was based on Phase 3 BREEZE-AD clinical development program evaluating the baricitinib potential to treat AD including BREEZE-AD1 and BREEZE-AD2.

            PharmaCompass